WZ66, a novel acetyl-CoA carboxylase inhibitor, alleviates nonalcoholic steatohepatitis (NASH) in mice

The global prevalence of nonalcoholic steatohepatitis (NASH) increases incredibly. NASH ends up to advanced liver disease, which is highly threatening to human health. Currently, treatment of NASH is very limited. Acetyl-CoA carboxylases (ACC1/ACC2) are proved as effective drug targets for NASH. We...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Acta Pharmacol Sin
Auteurs principaux: Gao, Ying-sheng, Qian, Min-yi, Wei, Qiang-qiang, Duan, Xu-bin, Wang, Shi-lei, Hu, Hai-yang, Liu, Jun, Pan, Chu-yue, Zhang, Shuo-quan, Qi, Lian-wen, Zhou, Jin-pei, Zhang, Hui-bin, Wang, Li-rui
Format: Artigo
Langue:Inglês
Publié: Springer Singapore 2019
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7468331/
https://ncbi.nlm.nih.gov/pubmed/31645659
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41401-019-0310-0
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires